硝酸舍他康唑(Sertaconazole Nitrate) - 药物靶点：fungal CYP51A1_在研适应症：足癣，真菌病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Dermofix、Dermoseptic、Fisderm

+ [11]

靶点

fungal CYP51A1

作用机制

fungal CYP51A1抑制剂(真菌细胞色素P450家族成员51抑制剂)

治疗领域

感染皮肤和肌肉骨骼疾病

在研适应症

足癣真菌病

非在研适应症

粘膜念珠菌病外阴阴道念珠菌病特应性皮炎

原研机构

Bausch Health Americas, Inc.

在研机构

Lacerta Therapeutics, Inc.初创企业

海南海神同洲制药有限公司

非在研机构

Spirig Pharma AG

最高研发阶段批准上市

首次获批日期

德国 (1995-11-03),

真菌病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C20H15Cl3N2OS

InChIKeyJLGKQTAYUIMGRK-UHFFFAOYSA-N

CAS号99592-32-2

查看全部结构式(2)

关联

13

项与硝酸舍他康唑相关的临床试验

CTRI/2022/10/046157

/ Not yet recruitingN/AIIT

A comparative study to evaluate the efficacy and safety of topical Sertaconazole versus Luliconazole in the patient of mild tinea corporis at a tertiary care center

开始日期2022-10-10

申办/合作机构-

TCTR20220121004

临床3期

Effect of adding the second dose of sertaconazole 300mg vaginal ovule for treating pregnant women with acute vaginal candidiasis who were treated with a 300mg sertaconazole vaginal ovule: a randomized controlled trial

开始日期2022-02-01

申办/合作机构-

CTRI/2021/03/032335

/ Not yet recruitingN/AIIT

A Controlled Trial to compare the efficacy and safety of Electrocautery with topical 2% Sertaconazole against topical 2% Sertaconazole alone in the treatment of localized Tinea Corporis: A Pilot Studyâ?? - CTESTC

开始日期2021-04-01

申办/合作机构-

100 项与硝酸舍他康唑相关的临床结果

登录后查看更多信息

100 项与硝酸舍他康唑相关的转化医学

登录后查看更多信息

100 项与硝酸舍他康唑相关的专利（医药）

登录后查看更多信息

165

项与硝酸舍他康唑相关的文献（医药）

2025-01-01·In Vivo

Sertaconazole, an Imidazole Antifungal Agent, Suppresses the Stemness of Breast Cancer Cells by Inhibiting Stat3 Signaling

Article

作者: Kim, Su-Lim ; Lee, Dong-Sun ; Choi, Hack Sun ; Hong, Won-Kyung

BACKGROUND/AIMBreast cancer stem cells (BCSCs) are a subpopulation of tumor cells that play a role in therapeutic resistance. In this study, we demonstrated that sertaconazole, an antifungal agent, displayed a potent inhibition on cancer stem cells (CSCs) and investigated the mechanism of action involved in its anti-BCSC effect.MATERIALS AND METHODSThe effect of sertaconazole on BCSCs was investigated using a mammosphere formation assay, a colony formation assay, and a cell migration assay. In addition, CD44^high/CD24^low and ALDEFLOR analyses, an apoptosis assay, quantitative real-time PCR, western blotting, an electrophoretic mobility shift assay, and a cytokine profiling assay were performed.RESULTSSertaconazole inhibited cell proliferation, colony formation, cell migration, mammosphere formation, and mammosphere proliferation. It also induced apoptosis of breast cancer cells. It decreased the subpopulation of CD44^high/CD24^low and aldehyde dehydrogenase-expressing cells. It also reduced the DNA binding of Stat3 and nuclear protein expression levels of phosphorylated Stat3. Furthermore, it reduced the IL-8 mRNA levels of the mammosphere.CONCLUSIONSertaconazole can inhibit the Stat3 and IL-8 signaling pathways and induce CSC death. Thus, sertaconazole might be a potential inhibitor of BCSCs.

2024-12-01·Antonie van Leeuwenhoek

Species distribution and antifungal susceptibility profiles of yeasts isolated from onychomycosis: a cross-sectional study with insights into emerging species

Article

作者: Kharazi, Mahboobeh ; Motamedi, Marjan ; Jabrodini, Ahmad ; Rezaei Arab, Maryam ; Shariat, Sahar ; Zomorodian, Kamiar ; Shabanzadeh, Shafigheh ; Ghasemi, Farnia ; Yazdanpanah, Somayeh

Candida onychomycosis is a common fungal infection affecting the nails, primarily caused by Candida (C.) species. Regarding the increasing trend of Candida onychomycosis and the antifungal resistant phenomenon in recent years, this study aims to evaluate the epidemiological characteristics of Candida onychomycosis, the distribution of emerging species, and the antifungal susceptibility profiles of isolates. Onychomycosis caused by yeast species was confirmed through direct examination and culture of nail scraping among all individuals suspected to have onychomycosis and referred to a medical mycology laboratory between June 2019 and March 2022. Species of yeast isolates were identified using the multiplex PCR and PCR-RFLP methods. The antifungal susceptibility of isolates to common antifungal agents and imidazole drugs was evaluated according to the M-27-A3 CLSI protocol. Among 101 yeast strains isolated from onychomycosis, Candida parapsilosis complex (50.49%) was the most common species, followed by C. albicans (20.79%) and C. tropicalis (10.89%). Rare species of yeasts such as C. guilliermondii and Saccharomyces cerevisiae were also identified by molecular methods. Results obtained from antifungal susceptibility testing showed significant differences in MIC values of isoconazole, fenticonazole, and sertaconazole among different species. Overall, a fluconazole-resistant rate of 3% was found among Candida species. Moreover, there was a statistically significant difference in MICs of fenticonazole and clotrimazole between the two most prevalent causative species, C. parapsilosis complex and C. albicans. Correct identification of the causative agents of onychomycosis and performing susceptibility testing could be helpful in choosing the most appropriate antifungal therapy.

2023-09-01·Medical Journal Armed Forces India

Comparative evaluation of the efficacy of itraconazole with terbinafine cream versus itraconazole with sertaconazole cream in dermatophytosis: A within person pilot study

Article

作者: Kothari, Rohit ; Vashisht, Deepak ; Baveja, Sukriti ; Venugopal, Ruby ; Kumar Joshi, Rajneesh

BackgroundCurrent trend of rising drug-resistant dermatophyte infection is alarming and fretted by dermatologists. Dilemma prevails regarding use of the same or different class of antifungal agents topically and systemically. The aim was to study the efficacy of oral itraconazole 200 mg with 1% terbinafine cream versus oral itraconazole 200 mg with 2% sertaconazole cream in dermatophytosis.MethodsThis within-person open-label pilot study enrolled 50 patients with dermatophytosis. Two lesions of comparable size within each patient were randomly allotted to group A and B and treated with 2% sertaconazole and 1% terbinafine cream, respectively. Both groups received itraconazole 200 mg once daily for 4 weeks. The remaining lesions received 1% terbinafine cream. Response and adverse effects were assessed at 2 and 4 weeks. Reduction in erythema, scaling, pruritus and clinical, and mycological cure constituted efficacy outcomes.ResultsThe mean duration of lesions was 2.82 ± 1.35 months. Complete clinical cure was observed in 50% and 48%, whereas mycological cure was attained in 56% and 52% patients in groups A and B, respectively, after 4 weeks, which was statistically insignificant. Reduction in erythema, scaling, and pruritus after 4 weeks when compared between the two groups, was also statistically insignificant.ConclusionSame class of oral and topical antifungal agents has comparable efficacy with different classes of oral and topical antifungal agents in dermatophyte infection.

100 项与硝酸舍他康唑相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08510	硝酸舍他康唑	D01AC14 G01AF19	DB01153

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
足癣	中国	海南海神同洲制药有限公司	2003-09-09
真菌病	德国	-	1995-11-03

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
粘膜念珠菌病	药物发现	中国	-	2013-10-09
外阴阴道念珠菌病	药物发现	中国	-	2013-09-28
特应性皮炎	药物发现	德国	Spirig Pharma AG	2013-02-01